Skip to main content

Table 2 Univariate and multivariate analyses for overall survival in patients with multiple myeloma obtained from the GSE24080 and GSE9782 datasets

From: Single cell RNA-seq data and bulk gene profiles reveal a novel signature of disease progression in multiple myeloma

Variables

Univariate analysis

Multivariable analysis

HR

95% CI

P value

HR

95% CI

P value

Training set GSE24080

20-gene risk model (high/low)

4.337

3.206–5.868

1.83e−21*

3.532

2.625–4.87

1.38e−14*

Age (y)

1.024

1.007–1.041

5.21e−03*

1.009

0.992–1.026

0.315

Sex (male/female)

0.971

0.716–1.317

0.850

IgA_Isotype (Y/N)

1.093

0.777–1.537

0.609

Serum β2MG ≥ 3.5 mg/L (Y/N)

2.211

1.633–2.994

2.92e−07*

1.548

1.034–2.32

0.034*

CRP ≥ 8.0 mg/L (Y/N)

1.485

1.096–2.011

0.011*

1.14

0.822–1.58

0.433

sCr ≥ 2.0 mg/L (Y/N)

2.746

1.866–4.039

2.93e−07*

1.442

0.929–2.237

0.102

LDH > upper limit of normal (> 190 U/L) (Y/N)

2.32

1.716–3.137

4.57e−08*

1.502

1.078–2.093

0.016*

Serum ALB < 3.5 g/L (Y/N)

1.927

1.329–2.794

5.41e−04*

1.255

0.835–1.886

0.274

Hemoglobin < 100 g/L (Y/N)

1.625

1.191–2.216

2.17e−03*

0.982

0.693–1.391

0.916

Bone marrow plasma cells (%)

1.01

1.004–1.016

9.14e−04*

1

0.993–1.007

0.952

Validation set GSE9782

20-gene risk model (high/low)

2.737

2.11–3.55

3.33e−14*

3.017

2.162–4.211

8.35e−11*

Serum β2M ≥ 3.5 mg/L (Y/N)

1.961

1.315–2.924

9.6e−04*

1.686

1.098–2.588

0.017*

CRP ≥ 8.0 mg/L (Y/N)

2.107

1.416–3.135

2.36e−04*

1.6

1.057–2.423

0.026*

Serum ALB < 3.5 g/L (Y/N)

1.798

1.298–2.49

4.17e−04*

1.618

1.058–2.476

0.026*

  1. HR hazard ratio, 95%CI 95% confidence interval, β2MG β2-microglobulin, CRP C-reactive protein, sCr serum creatinine, LDH lactate dehydrogenase, ALB albumin; *, statistically significant